3rd Quarter - Report

W STRATEGIES, LLC for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule. H.R.2430/S.934: FDA Reauthorization Act of 2017. H.R.1628: American Health Care Act and Better Care Reconciliation Act.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2430 (115th), H.R. 1628 (115th), S. 934 (115th)

Medicare/Medicaid MMM

H.R.1834: Cancer Care Payment Reform Act of 2017. Synchronization and Nonadherence Correction (SYNC) Act. H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1834 (115th), H.R. 849 (115th), H.J.Res. 51 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.